Raptor Pharmaceutical (RPTP) 9.05 $RPTP
PROCYSBI(R) to Receive New Treatment Award From Lysosomal Disease Network at the 11th Annual WORLD Symposium
GlobeNewswire - Tue Feb 10, 8:51AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the Lysosomal Disease Network (LDN) will present Raptor Pharmaceutical with the 2015 New Treatment Award for PROCYSBI (cysteamine bitartrate) delayed-release capsules on February 12, 2015 at its 11 Annual WORLD Symposium being held in Orlando, Fla. on February 9-13, 2015. This award, which is presented annually, recognizes new therapies that have made a considerable contribution in the area of lysosomal diseases.
RPTP: 9.05 (-0.40)
The 2015 Calendar Of NASH Trial Catalysts: Intercept's Breakthrough Designation Hastens Decision Process
Clinically Sound Investor - at Seeking Alpha - Fri Jan 30, 2:34PM CST
GLMD: 6.80 (+0.03), RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12)
Raptor Pharmaceutical to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Fri Jan 30, 12:30PM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will present at the following conference:
RPTP: 9.05 (-0.40)
The 2015 Calendar Of NASH Trial Catalysts: Takeda And Tobira
Clinically Sound Investor - at Seeking Alpha - Fri Jan 23, 11:43AM CST
RPTP: 9.05 (-0.40), RGDO: 1.17 (+0.02)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 3.10 (+0.07), RPTP: 9.05 (-0.40), SRPT: 12.76 (+0.11), CLDX: 20.97 (+0.53), PTCT: 53.37 (-0.74), RMTI: 11.17 (+0.15), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
Raptor Pharmaceuticals - How To Explain Its Reported Revenues?
The Visible Hand - Seeking Alpha - Tue Jan 20, 8:33AM CST
The author of this posting is a private fund manager. At the time of publication, funds and accounts managed by the author were short Raptor Pharmaceuticals Corp. ("RPTP"
. Such funds and accounts may buy and sell securities of RPTP (and...
RPTP: 9.05 (-0.40)
Raptor Pharmaceutical Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire - Tue Jan 20, 7:00AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that on January 15, 2015, a majority of the independent members of the Company's Board of Directors approved inducement stock option awards to new hire employees pursuant to the Raptor Pharmaceutical Corp. 2014 Employment Commencement Stock Incentive Plan. The plan was approved by the Board of Directors under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
RPTP: 9.05 (-0.40)
Regado Bio and Tobira to merge
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 8:42AM CST
RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), SHPG: 239.82 (+6.11), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), RGDO: 1.17 (+0.02)
Did Gilead Sciences Just Buy Its Next Blockbuster Drug?
Keith Speights, The Motley Fool - Motley Fool - Sat Jan 10, 12:06PM CST
Important events don't always seem so important when they first occur. That could be the case with Gilead Sciences ' announcement on Tuesday that it was buying Phenex Pharmaceuticals' development program for nonalcoholic steatohepatitis, or NASH....
RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), ICPT: 209.12 (+7.12)
Raptor Pharmaceutical Appoints Krishna Polu, M.D. as Chief Medical Officer and Michael Smith as Chief Financial Officer
GlobeNewswire - Wed Jan 07, 7:00AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced the appointment of Krishna R. Polu, M.D., as its Chief Medical Officer and Michael P. Smith as Chief Financial Officer, effective January 12, 2015. Dr. Polu will oversee all global clinical development programs, medical affairs and other related functions. Mr. Smith will serve as Raptor's principal financial and accounting officer. Both will report to Julie Anne Smith, Raptor's President and Chief Executive Officer.
RPTP: 9.05 (-0.40)
Gilead Acquires Drug Program For Fatty Liver Disease
at Investor's Business Daily - Tue Jan 06, 10:20AM CST
Big-cap biotech Gilead Sciences (GILD) agreed Tuesday to acquire a program from small German biotech Phenex Pharmaceuticals aimed at treating liver disease. Gilead agreed to an unspecified upfront payment and milestone payments totaling up to $470...
RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), CNAT: 5.92 (+0.10), ICPT: 209.12 (+7.12), FGEN: 30.25 (+0.50)
IPO Stock Watch: FibroGen Up With Liver-Disease Field
at Investor's Business Daily - Mon Jan 05, 3:40PM CST
Biotech FibroGen (FGEN) jumped 23% Monday to 33.83, a new high for a stock that went public at 18 on Nov. 13. FibroGen stock rose along with several other players in the liver-disease field, including Intercept Pharmaceuticals (ICPT), Conatus (CNAT)...
RPTP: 9.05 (-0.40), CNAT: 5.92 (+0.10), ICPT: 209.12 (+7.12), FGEN: 30.25 (+0.50)
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvqp4h/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Cardax - Connexios Life Sciences - Cubist - Daiichi Sankyo Company - Dr. Falk Pharma - Galectin Therapeutics - Galmed - Genfit - Gilead Sciences - Immuron - Intercept Pharmaceuticals - Isis Pharmaceuticals - Jenrin Discovery - Kadmon Corporation - Kissei Pharmaceutical - Kyorin Pharmaceutical - La Jolla Pharmaceutical - Mochida Pharmaceutical - NasVax - Novo Nordisk - Phenex Pharmaceuticals - ProMetic Life Sciences - Raptor Pharmaceuticals - Shire - Stelic Institute & Co - Tobira Therapeutics - Verva Pharmaceuticals - Wellstat Therapeutics - Zafgen - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/tv...nalcoholic
NVO: 43.76 (+0.61), RPTP: 9.05 (-0.40), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), TBRA: ()
Interesting RPTP Put And Call Options For August 2015
at The Street - Tue Dec 30, 10:02AM CST
Investors in Raptor Pharmaceuticals Corp. saw new options begin trading this week, for the August 2015 expiration.
RPTP: 9.05 (-0.40)
Trade-Ideas: Raptor Pharmaceutical (RPTP) Is Today's Strong On High Relative Volume Stock
at The Street - Mon Dec 29, 9:07AM CST
Trade-Ideas LLC identified Raptor Pharmaceutical (RPTP) as a strong on high relative volume candidate
RPTP: 9.05 (-0.40)
Commit To Purchase Raptor Pharmaceuticals At $7.50, Earn 33.3% Using Options
at The Street - Wed Dec 24, 11:18AM CST
Investors considering a purchase of Raptor Pharmaceuticals Corp. shares, but tentative about paying the going market price of $9.32/share, might benefit from considering selling puts among the alternative strategies at their disposal.
RPTP: 9.05 (-0.40)
The 2015 Calendar Of NASH Trial Catalysts Series Brings Huge Opportunities For Investors
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 2:29AM CST
RPTP: 9.05 (-0.40), CNAT: 5.92 (+0.10)
Raptor Pharmaceutical Appoints Gregg Lapointe and Georges Gemayel to Board of Directors
GlobeNewswire - Thu Dec 18, 6:30AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced the appointment of Gregg Lapointe and Georges Gemayel, Ph.D. to its Board of Directors, effective January 1, 2015. As previously disclosed, they will be joining Julie Anne Smith, President and CEO-Designate as she succeeds Christopher Starr, Ph.D., as Chief Executive Officer and joins the Board effective January 1, 2015.
RPTP: 9.05 (-0.40)
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.84 (-0.01), PFNX: 12.45 (+0.29), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), RPTP: 9.05 (-0.40), IBIO: 0.90 (+0.36), ANAC: 40.76 (-0.07), PFE: 34.64 (-0.23), GNCA: 8.93 (-0.07), GSK: 47.94 (+1.99), AZN: 69.96 (+0.20), NVS: 102.20 (-0.17)
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/48lh7t/non_alcoholic) has announced the addition of the "Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - F. Hoffmann-La Roche - Merck & Co - Novartis - Daewoong Pharmaceutical - Orchid Chemicals & Pharmaceuticals - Phynova Group - Raptor Pharmaceuticals - Phenex Pharmaceuticals - Metabolic Solutions Development - Zafgen - Verva Pharmaceuticals - Galmed International - TCM Biotech International For more information visit http://www.researchandmarkets.com/research/48..._alcoholic
RPTP: 9.05 (-0.40), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
PROCYSBI(R) to Receive New Treatment Award From Lysosomal Disease Network at the 11th Annual WORLD Symposium
GlobeNewswire - Tue Feb 10, 8:51AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the Lysosomal Disease Network (LDN) will present Raptor Pharmaceutical with the 2015 New Treatment Award for PROCYSBI (cysteamine bitartrate) delayed-release capsules on February 12, 2015 at its 11 Annual WORLD Symposium being held in Orlando, Fla. on February 9-13, 2015. This award, which is presented annually, recognizes new therapies that have made a considerable contribution in the area of lysosomal diseases.
RPTP: 9.05 (-0.40)
The 2015 Calendar Of NASH Trial Catalysts: Intercept's Breakthrough Designation Hastens Decision Process
Clinically Sound Investor - at Seeking Alpha - Fri Jan 30, 2:34PM CST
GLMD: 6.80 (+0.03), RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12)
Raptor Pharmaceutical to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Fri Jan 30, 12:30PM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will present at the following conference:
RPTP: 9.05 (-0.40)
The 2015 Calendar Of NASH Trial Catalysts: Takeda And Tobira
Clinically Sound Investor - at Seeking Alpha - Fri Jan 23, 11:43AM CST
RPTP: 9.05 (-0.40), RGDO: 1.17 (+0.02)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 3.10 (+0.07), RPTP: 9.05 (-0.40), SRPT: 12.76 (+0.11), CLDX: 20.97 (+0.53), PTCT: 53.37 (-0.74), RMTI: 11.17 (+0.15), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
Raptor Pharmaceuticals - How To Explain Its Reported Revenues?
The Visible Hand - Seeking Alpha - Tue Jan 20, 8:33AM CST
The author of this posting is a private fund manager. At the time of publication, funds and accounts managed by the author were short Raptor Pharmaceuticals Corp. ("RPTP"
. Such funds and accounts may buy and sell securities of RPTP (and... RPTP: 9.05 (-0.40)
Raptor Pharmaceutical Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire - Tue Jan 20, 7:00AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that on January 15, 2015, a majority of the independent members of the Company's Board of Directors approved inducement stock option awards to new hire employees pursuant to the Raptor Pharmaceutical Corp. 2014 Employment Commencement Stock Incentive Plan. The plan was approved by the Board of Directors under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
RPTP: 9.05 (-0.40)
Regado Bio and Tobira to merge
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 8:42AM CST
RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), SHPG: 239.82 (+6.11), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), RGDO: 1.17 (+0.02)
Did Gilead Sciences Just Buy Its Next Blockbuster Drug?
Keith Speights, The Motley Fool - Motley Fool - Sat Jan 10, 12:06PM CST
Important events don't always seem so important when they first occur. That could be the case with Gilead Sciences ' announcement on Tuesday that it was buying Phenex Pharmaceuticals' development program for nonalcoholic steatohepatitis, or NASH....
RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), ICPT: 209.12 (+7.12)
Raptor Pharmaceutical Appoints Krishna Polu, M.D. as Chief Medical Officer and Michael Smith as Chief Financial Officer
GlobeNewswire - Wed Jan 07, 7:00AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced the appointment of Krishna R. Polu, M.D., as its Chief Medical Officer and Michael P. Smith as Chief Financial Officer, effective January 12, 2015. Dr. Polu will oversee all global clinical development programs, medical affairs and other related functions. Mr. Smith will serve as Raptor's principal financial and accounting officer. Both will report to Julie Anne Smith, Raptor's President and Chief Executive Officer.
RPTP: 9.05 (-0.40)
Gilead Acquires Drug Program For Fatty Liver Disease
at Investor's Business Daily - Tue Jan 06, 10:20AM CST
Big-cap biotech Gilead Sciences (GILD) agreed Tuesday to acquire a program from small German biotech Phenex Pharmaceuticals aimed at treating liver disease. Gilead agreed to an unspecified upfront payment and milestone payments totaling up to $470...
RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), CNAT: 5.92 (+0.10), ICPT: 209.12 (+7.12), FGEN: 30.25 (+0.50)
IPO Stock Watch: FibroGen Up With Liver-Disease Field
at Investor's Business Daily - Mon Jan 05, 3:40PM CST
Biotech FibroGen (FGEN) jumped 23% Monday to 33.83, a new high for a stock that went public at 18 on Nov. 13. FibroGen stock rose along with several other players in the liver-disease field, including Intercept Pharmaceuticals (ICPT), Conatus (CNAT)...
RPTP: 9.05 (-0.40), CNAT: 5.92 (+0.10), ICPT: 209.12 (+7.12), FGEN: 30.25 (+0.50)
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvqp4h/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Cardax - Connexios Life Sciences - Cubist - Daiichi Sankyo Company - Dr. Falk Pharma - Galectin Therapeutics - Galmed - Genfit - Gilead Sciences - Immuron - Intercept Pharmaceuticals - Isis Pharmaceuticals - Jenrin Discovery - Kadmon Corporation - Kissei Pharmaceutical - Kyorin Pharmaceutical - La Jolla Pharmaceutical - Mochida Pharmaceutical - NasVax - Novo Nordisk - Phenex Pharmaceuticals - ProMetic Life Sciences - Raptor Pharmaceuticals - Shire - Stelic Institute & Co - Tobira Therapeutics - Verva Pharmaceuticals - Wellstat Therapeutics - Zafgen - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/tv...nalcoholic
NVO: 43.76 (+0.61), RPTP: 9.05 (-0.40), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), TBRA: ()
Interesting RPTP Put And Call Options For August 2015
at The Street - Tue Dec 30, 10:02AM CST
Investors in Raptor Pharmaceuticals Corp. saw new options begin trading this week, for the August 2015 expiration.
RPTP: 9.05 (-0.40)
Trade-Ideas: Raptor Pharmaceutical (RPTP) Is Today's Strong On High Relative Volume Stock
at The Street - Mon Dec 29, 9:07AM CST
Trade-Ideas LLC identified Raptor Pharmaceutical (RPTP) as a strong on high relative volume candidate
RPTP: 9.05 (-0.40)
Commit To Purchase Raptor Pharmaceuticals At $7.50, Earn 33.3% Using Options
at The Street - Wed Dec 24, 11:18AM CST
Investors considering a purchase of Raptor Pharmaceuticals Corp. shares, but tentative about paying the going market price of $9.32/share, might benefit from considering selling puts among the alternative strategies at their disposal.
RPTP: 9.05 (-0.40)
The 2015 Calendar Of NASH Trial Catalysts Series Brings Huge Opportunities For Investors
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 2:29AM CST
RPTP: 9.05 (-0.40), CNAT: 5.92 (+0.10)
Raptor Pharmaceutical Appoints Gregg Lapointe and Georges Gemayel to Board of Directors
GlobeNewswire - Thu Dec 18, 6:30AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced the appointment of Gregg Lapointe and Georges Gemayel, Ph.D. to its Board of Directors, effective January 1, 2015. As previously disclosed, they will be joining Julie Anne Smith, President and CEO-Designate as she succeeds Christopher Starr, Ph.D., as Chief Executive Officer and joins the Board effective January 1, 2015.
RPTP: 9.05 (-0.40)
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.84 (-0.01), PFNX: 12.45 (+0.29), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), RPTP: 9.05 (-0.40), IBIO: 0.90 (+0.36), ANAC: 40.76 (-0.07), PFE: 34.64 (-0.23), GNCA: 8.93 (-0.07), GSK: 47.94 (+1.99), AZN: 69.96 (+0.20), NVS: 102.20 (-0.17)
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/48lh7t/non_alcoholic) has announced the addition of the "Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - F. Hoffmann-La Roche - Merck & Co - Novartis - Daewoong Pharmaceutical - Orchid Chemicals & Pharmaceuticals - Phynova Group - Raptor Pharmaceuticals - Phenex Pharmaceuticals - Metabolic Solutions Development - Zafgen - Verva Pharmaceuticals - Galmed International - TCM Biotech International For more information visit http://www.researchandmarkets.com/research/48..._alcoholic
RPTP: 9.05 (-0.40), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
